secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001104659-24-008787
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Therapeutics signs $300M upfront collaboration with Takeda for rusfertide
--------------------------------------------------------------------------------

- Takeda pays $300M upfront within 30 days of HSR clearance; 50/50 profit-loss share in U.S.
- Tiered royalties of 10-17% in ex-US territory; up to 29% if opt-out exercised.
- Milestones up to $330M (no opt-out) or up to $975M (with opt-out); plus $400M opt-out payment potential.
- Takeda leads global commercialization; Protagonist holds option to co-detail in U.S.
- Takeda may terminate for convenience after Phase 3 data or 3rd anniversary of effective date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924008787/0001104659-24-008787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924008787/tm244678d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-008787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer